Autoimmune Diseases Clinical Trial
Official title:
Incidence and Frequency of Cariogenic Microflora in Patients With Clinical Xerostomia and Autoimmune Disease
This study will examine the types of bacteria present in the dental plaque of patients with
persistent dry mouth. Saliva is essential for digestion and swallowing and for maintaining
the normal mineralization of teeth. People who suffer from dry mouth usually have a
significant increase in tooth decay (caries). This study will determine if this increase is
due solely to reduced salivary flow or also to an increase in certain types of bacteria in
the mouth.
Patients participating in the following NIDCR protocols may be eligible for this study:
Evaluation and Treatment of Salivary Dysfunction (84-D-0056), Natural History of Salivary
Gland Dysfunction and Sjogren's Syndrome Research Project (99-D-0070), and Salivary
Evaluation in Normal Volunteers (94-D-0018).
Participants will have three appointments at the NIH dental clinic as follows:
Visit 1
Dental examination and instruction on keeping a detailed diary of food intake.
Visit 2 (1 week after visit 1)
Attachment of a bacteria collection device (described below) to the side of a tooth.
Visit 3 (48 hours after visit 2)
Removal of the collection device, tooth cleaning and polishing, and submission of food
diary.
The bacteria collection device is a 4mm x 2mm x 2mm square of sterilized tooth obtained from
slicing an extracted healthy tooth donated by another patient. The donated teeth are either
extracted impacted third molars (wisdom teeth) or teeth extracted for teeth straightening
(orthodontics). The device is heat-sterilized before being bonded to the participant's
tooth. The dental cement used for bonding can be removed after 48 hours with no damage to
the surface of the participant's tooth.
Status | Completed |
Enrollment | 44 |
Est. completion date | August 2004 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Selection of subjects for the study will be restricted to the pool of NIDCR patients
already participating in protocol 84-D-0056, Evaluation and Treatment of Salivary
Dysfunction. INCLUSION CRITERIA A. Salivary Flow = 0.1ml/min pooled unstimulated; and B. A diagnosis of SS (primary or secondary) C. A diagnosis of non-SS auto-immune disease D. The use of a medication with known xerostomic effect E. Subjective xerostomia or xerophthalmia F. The presence of permanent teeth. EXCLUSION CRITERIA A. Child and Adolescent: Children and Adolescents will not be included in the study due to the presence of deciduous teeth which are less suitable for bonding and which show an altered enamel morphology and pattern of plaque accumulation |
N/A
Country | Name | City | State |
---|---|---|---|
United States | National Institute of Dental And Craniofacial Research (NIDCR) | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Dental and Craniofacial Research (NIDCR) |
United States,
Almståhl A, Kroneld U, Tarkowski A, Wikström M. Oral microbial flora in Sjögren's syndrome. J Rheumatol. 1999 Jan;26(1):110-4. — View Citation
Babaahmady KG, Challacombe SJ, Marsh PD, Newman HN. Ecological study of Streptococcus mutans, Streptococcus sobrinus and Lactobacillus spp. at sub-sites from approximal dental plaque from children. Caries Res. 1998;32(1):51-8. — View Citation
Boutsi EA, Paikos S, Dafni UG, Moutsopoulos HM, Skopouli FN. Dental and periodontal status of Sjögren's syndrome. J Clin Periodontol. 2000 Apr;27(4):231-5. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04078698 -
Documentation of the Safety and Effectiveness Profile of the IgG Immunoadsorber GLOBAFFIN® in Clinical Routine
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A | |
Recruiting |
NCT05670301 -
Flemish Joint Effort for Biomarker pRofiling in Inflammatory Systemic Diseases
|
N/A | |
Completed |
NCT03266172 -
A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses
|
Phase 1 | |
Completed |
NCT03649412 -
A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772
|
Phase 1 | |
Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
Completed |
NCT03173144 -
Chronic Inflammatory Disease, Lifestyle and Treatment Response
|
||
Completed |
NCT00975936 -
Phase 0 Microdose Study
|
Phase 1 | |
Not yet recruiting |
NCT05969821 -
Clonal Hematopoiesis of Immunological Significance
|
||
Completed |
NCT01210716 -
Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device
|
Phase 3 | |
Completed |
NCT00820469 -
Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab
|
Phase 4 | |
Completed |
NCT01953523 -
Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions
|
N/A | |
Withdrawn |
NCT03239600 -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS)
|
Phase 2 | |
Completed |
NCT04872257 -
Oral Vitamin D Supplementation Combined With Phototherapy as a Treatment for Vitiligo
|
N/A | |
Recruiting |
NCT06019611 -
Epidural Stimulation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05030779 -
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus
|
Early Phase 1 | |
Not yet recruiting |
NCT03899298 -
Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions
|
Phase 1 | |
Completed |
NCT04005456 -
Personalized Lifestyle Intervention for Improving Functional Health Outcomes Using N-of-1 Tent-Umbrella-Bucket Design
|
N/A | |
Recruiting |
NCT05085444 -
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma
|
Early Phase 1 | |
Recruiting |
NCT05853835 -
First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641
|
Phase 1 |